Isis and Roche partner to 'shuttle' Huntington's therapies
This article was originally published in Scrip
Executive Summary
Roche will pay up to $392 million in upfront and milestone fees plus royalties to Isis Pharmaceuticals in a deal that pairs the latter's antisense technology with the former's "brain shuttle" program to develop Huntington's disease therapies.